Antibody-drug conjugate (ADC) company, Mersana Therapeutics and Adimab have initiated a joint effort to offer integrated antibody discovery and ADC technologies.
The partnership will provide pharmaceutical companies an access to Adimab's antibodies, which have been specifically optimized for use in ADCs together with Mersana's Fleximer polymer and array of customizable linkers for attaching diverse, potent payloads.
Adimab CEO Tillman Gerngross said the flexibility in payloads, linkers and drug loading enabled by Mersana's Fleximer technology complements Adimab's philosophy of tailoring drug development to the biology of the target of interest.
''We view ADCs, as well as other aspects of antibody discovery such as bispecific formats, as important tools in the development of novel therapeutics," Gerngross added.
Mersana CEO Nicholas Bacopoulos said Mersana is excited to combine Adimab's technology with its differentiated ADC platform consisting of clinically validated Fleximer polymer, diverse linkers and variety of payloads.
'' Adimab's tailored approach fits perfectly with the customized design of Fleximer ADCs and together we can provide ADCs with increased likelihood of target selectivity and therapeutic efficacy, '' Bacopoulos added.
